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Elucidation of endogenous cellular protein-protein
interactions and their networks is most desirable for
biological studies. Herewe report our studyof endog-
enous human coregulator protein complex networks
obtained from integrative mass spectrometry-based
analysis of 3290 affinity purifications. By preserving
weak protein interactions during complex isolation
andutilizinghigh levels of reciprocity in the largedata-
set, we identified many unreported protein associa-
tions, such as a transcriptional network formed by
ZMYND8, ZNF687, and ZNF592. Furthermore, our
work revealed a tiered interplay within networks that
sharecommonproteins,providingaconceptualorga-
nization of a cellular proteome composed of minimal
endogenous modules (MEMOs), complex isoforms
(uniCOREs), and regulatory complex-complex inter-
action networks (CCIs). This resource will effectively
fill a void in linking correlative genomic studies with
anunderstandingof transcriptional regulatoryprotein
functions within the proteome for formulation and
testing of future hypotheses.
INTRODUCTION
Protein-protein interactions constitute the molecular backbone
of cell biology, where select proteins assemble into metastable
complexes to form bioactive units (Alberts, 1998; Ko¨cher and
Superti-Furga, 2007). These complexes then dynamically asso-
ciate with each other in context of larger networks to carry out
diverse biological functions. Thus, understanding the basic
mechanisms of cell homeostasis requires knowledge of both
the composition of protein complexes and the interactions
between them.
A systems biology view of protein interactions has begun to
emerge from large-scale studies in model organisms such as
yeast, worms, and fruit flies (Gavin et al., 2006; Giot et al.,2003; Ito et al., 2001; Krogan et al., 2006; Li et al., 2004; Uetz
et al., 2000). These analyses were made possible due to the
development of high-throughput (HT) methods for measuring
protein-protein interactions by affinity purification of tagged
protein baits followed by mass spectrometry (AP/MS) and yeast
two-hybrid assays. Limitations in genetic manipulations hinder
such studies in human cells. We thus developed a protocol for
HT isolation and identification of endogenous protein complexes
from human cell lines using primary antibody immunoprecipita-
tion and mass spectrometry (IP/MS). We also addressed key
limitations associated with such studies, which are cross-reac-
tivity of primary antibodies and nonspecific binding, and
proposed an approach for the deconvolution of HT-IP/MS data
into discrete protein complexes (Malovannaya et al., 2010).
Our current work was inspired by—and for a large part
included—the Nuclear Receptor Signaling Atlas (NURSA;
http://www.nursa.org) consortium proteomics effort, whose
goal is to systematically isolate and identify the human nuclear
receptor (NR) coregulator complexome. NR coregulators are
a diverse group of molecules that associate with sequence-
specific transcription factors to collectively modulate target
gene expression (Lonard and O’Malley, 2007; Lonard et al.,
2007; McKenna et al., 1999; O’Malley et al., 2008; Weake and
Workman, 2010). Initial biochemical isolations of the mammalian
coactivators Mediator and BAF/P-BAF and HDAC corepressors
revealed that many coregulators assemble into multisubunit
protein complexes (Gu et al., 1999; Guenther et al., 2000; Wang
et al., 1996; Xue et al., 1998), implying that a comprehensive
picture of the protein interaction networks is needed to better
understand the regulation of biological processes in the cell.
This study presents the most extensive interaction dataset for
endogenous regulatory human proteins obtained to date. By
preserving both stable and weak protein interactions during
complex isolations, we unveiled a modular and hierarchical orga-
nization of protein complex networks that serve as a blueprint for
a better understanding of mechanisms of mammalian cell regula-
tion.Our approachcanbeused inotherbiological systemsaswell;
with broad applicability in mind we therefore discuss the analysis
schema we used for the definition and annotation of protein
complexes. Knowing the composition of protein complexes andCell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc. 787
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Figure 1. HT-IP/MS Analysis of the Human Endogenous Complexome
(A) Our workflow consists of IP/MS followed by filtering of nonspecific identifications, definition of minimal core complex modules (MEMOs), and assignment of
complex-complex interactions (CCIs). Data relationships are abbreviated as ‘‘exp-2-gene,’’ ‘‘ab-2-gene,’’ and ‘‘ab-2-memo’’ for experiment-to-genes, antibody-
to-genes, and antibody-2-MEMOs, respectively.
(B) Representative SDS-PAGE of NR coregulator complexes. IgG HC and LC are heavy and light chains of primary antibodies.
(C) Approximately 40% of the human gene products were recovered in our HT-IP/MS data in 100,000 specific protein identifications. Majority of these were
found in at least two or more antibody-different experiments, laying a foundation for finding reciprocally verified protein associations (additional descriptive
statistics and data are available in Figure S1 and Table S1).their interaction networks ultimately will allow for an effective
translation of genomic data to functional molecular biology.
Such resources, therefore, have thepotential to transform the field
of basic research and greatly impact translational efforts.
RESULTS AND DISCUSSION
A Comprehensive HT-IP/MS of the Human Endogenous
Complexome
To initiate delineation of the ‘‘regulatory’’ human protein com-
plexome, we preferentially targeted transcriptional and signaling
proteins. We used 1796 primary antibodies in 3290 immunopre-
cipitation experiments (Figure 1 and Table S1 and Table S2 avail-
able online) to obtain a total of 300,000 protein identifications,
about 100,000 of which we deemed specific after in silico data
filtering (Figures 1A and 1C). These identifications represent
11,485 unique human gene products, more than half of which
we recovered redundantly by using different antibodies.788 Cell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc.To assess the overall discovery potential, we compared all
possible unique pairs of protein associations from our dataset
with human protein interactions found in the CORUM, BioGRID,
IntAct, and HPRD resources (Figure S1). Our dataset covers
about 70% of the protein associations reported in CORUM
(Ruepp et al., 2010), whereas most of our high-confidence inter-
actions are not listed in this nor any other current public reposi-
tories. Based on this comparison alone, our single-source study
recovered the majority of protein complexes previously reported
in the literature but, at the same time, significantly expanded the
human interactome.
Deconvolution of the IP/MSData into Organized Cellular
Complexome
The nature of IP/MS data output—a list of protein identifications
without indications of specific interactions within and between
complexes—commands a different logic for data analysis as
compared to conventional protein-protein interaction (PPI)
mapping. We thus developed an analysis schema that reveals an
intrinsic tiered organization of the interactome in three discrete
layers. These are (1) the minimal endogenous core complex
modules (‘‘MEMOs’’), (2) the unique core complex isoforms
(‘‘uniCOREs’’), and (3) thecomplex-complex interaction networks
(CCIs) (Figure S2A). Such classification respects protein complex
modularity and heterogeneity, which constitute a fundamental
program of cellular organization, and aids in delineation of
higher-order protein interactions on a proteome-wide level.
Minimal Endogenous Modules and Core Complex
Isoforms
A core protein complex is loosely defined in biochemistry as
strongly associated proteins that resist separation in column
fractionations. Many core complexes, however, exhibit some
level of variability in only a few components of otherwise similar
protein assemblies. Such complex ‘‘isoforms’’ can be isolated
and shown to function exclusively of each other. For example,
we recovered the MSL and NSL complexes that contain
transcriptional regulator MYST1 histone acetyltransferase and
recently have been shown to display different substrate specific-
ities (Cai et al., 2010; Mendjan et al., 2006). To better convey
such modularity, we identified variable components in protein
complexes and formed a dataset of MEMOs. These modules
represent invariant minimal complexes of proteins with stoichio-
metric interdependence across the entire IP/MS dataset and
serve as the conceptual building blocks of the protein com-
plexome. Ultimately, each of the human protein-coding gene
products will be assigned to one MEMO only. MEMOs are then
used to reconstitute all distinct protein complex isoforms, which
we call uniCOREs. The multisubunit protein complexes con-
ventionally described in the literature most closely correspond
to uniCOREs in our resource and likely impart biological func-
tional classification.
We recently have shown that high-confidence protein interac-
tion information can be derived from systematic IP/MS studies
by enforcing two key constraints: reciprocal coappearance of
proteins in multiple antibody-different IPs and preservation of
stoichiometry of the core components (Malovannaya et al.,
2010). Operationally, MEMOs are identified by running reciprocal
near neighbor network (3N) analyses iteratively over the entire
dataset to find sets of proteins with the highest correlations in
different experiments. Proteins that do not show consistency in
stoichiometric interactions form ‘‘singletons,’’ which are MEMOs
with special implications, discussed later using SPEN and
SRC-3 as examples.
De Novo Derivation of Complex-Complex Interactions
Although much insight is gained from the core protein
complexes, a more daunting task is to acquire information of
the CCIs. In fact, CCIs may represent the backbone of regulatory
biology; yet, on no account have they been systematically
addressed. We show here that CCIs can be derived de novo
from HT-IP/MS data.
Transient interactions between protein complexes do not
show a stoichiometric dependence; we therefore used Boolean
metrics on co-occurrences of MEMOs to find complex-complex
interactions. Briefly, we first calculated reciprocity and a series ofJaccard indices for all protein associations (see Extended Exper-
imental Procedures). Furthermore, we adopted a matrix model
score previously described as part of socio-affinity index
(Gavin et al., 2006) to capture above-chance associations and
defined a CCI rank that combines protein interaction scores for
all subunits of a given MEMO as a chance indicator for true
associations between MEMOs (Extended Experimental Proce-
dures). We have precalculated all CCIs for each gene product
in our HT-IP/MS dataset and formed a resource of human
endogenous MEMOs and CCI networks that allows researchers
to interrogate our data (see Figure S6). Subsequent iterative
searching for different MEMO components can be used to iden-
tify uniCOREs, as described next.
Example of Assignment of uniCOREs through
Reciprocal Exclusion in CCI Networks: The BRCA1
Extended Interaction Network
BRCA1 (breast cancer 1) has been extensively studied in DNA-
damage responses as well as transcriptional regulation. Multiple
IP/MS experiments showed that the BRCA1 interactome is more
heterogeneous and modular than previously thought. BRCA1
and BARD1 (BRCA1 associated RING domain 1) show stoichio-
metric interdependency and constitute a MEMO, and they are
found in a pool of apparently stable complexes either with
BRCA1-interacting protein 1 (BRIP1), PALB2/BRCA2, RBBP8,
BRE/BRCC3/C19orf62, FAM175A (Abraxas), FAM175B
(Abraxas brother 1), or UIMC1 (Figure 2A and Figure S2). These
proteins do not have consistent stoichiometric relationships with
each other, suggesting that they likely form different BRCA1
uniCOREs.
The interactions between UIMC1, FAM175A, FAM175B, and
BRCC3/BRE/C19orf62 (‘‘BRCA1-A’’ complex) have been
described in the literature (Feng et al., 2009; Kim et al., 2007;
Shao et al., 2009b; Wang et al., 2007, 2009a; Yan et al., 2007).
In our dataset, FAM175A and FAM175B interact with UIMC1 in
a mutually exclusive manner, and they resolve independently
from each other in respective 3N analyses (Figures 2B and 2C).
The FAM175A-UIMC1-BRCC3/BRE/C19orf62 uniCORE does
not strongly bind known DNA-damage response components
but coprecipitates CDC6/7 kinases, bridging into checkpoint
BRCA1 functions (Figure 2D). In addition, we observed that
this uniCORE preferentially interacts with the BRCA1/BARD1
MEMO, whereas the FAM175B-containing uniCORE can be
found without UIMC1 and BRCA1 (Figure 2C). Specific functions
of the latter complex, particularly in the BRCA1-independent
context, are unknown.
Beyond UIMC1, BRCA1/BARD1 together with PALB2/BRCA2
bridge into mismatch repair processes via BRIP1 (‘‘BRCA1-B’’
complex) and interactions with MLH1/PMS2 (Figure S2).
BRCA1/BARD1/PALB2/BRCA2 also exists in a close CCI
network with RBBP8 (‘‘BRCA1-C’’ complex), the double-
stranded break sensor MRN (MRE11-RAD50-NBS1) complex,
CHEK1, RAD51, KEAP1, and MORF4L1/L2, implementing
a BRCA DNA repair function. KEAP1, an E3 ubiquitin ligase
adaptor (Cullinan et al., 2004; Kobayashi et al., 2004; Zhang
et al., 2004), appears to be a component of the BRCA1 interac-
tome; its function in this network remains to be investigated.
Interestingly, the MORF4L1/2 MEMO itself has at least twoCell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc. 789
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Figure 2. Protein Complex Heterogeneity in the BRCA1 Network
Partial BRCA1-related CCI networks, where individual MEMOs are separated by horizontal lines, are shown to highlight relationships betweenmajor components
of the BRCA1 interactome (see also Figure S2). (*) Column headers specify antibody names, not the intended antigens that were used to generate the antibody.
Despite conventions, it is often misleading to label IP/MS experiments with intended antigens because majority of antibodies cross-react with two or more
proteins and some do not IP the intended antigen at all (see Table S1 for more information on cross-reacting antigens).
(A) Discernible ‘‘hierarchical’’ organization of protein interactions illustrated by a selection of IPs containing BRCA1 uniCOREswith the highest SPC identifications
for all precipitated proteins (compare TopAntibodies lanes with MaxSPC lane). Although all proteins are equally true interactors of BRCA1, extensive reciprocal
evidence visually implicates exclusive patterns: first three columns are BRCA1 and BARD1 IPs (1), where all BRCA1-containing complexes are shared, whereas
experiments that target specific uniCOREs (2) show nonuniform distributions of BRCA1 interactors. To the right is a schematic interpretation of the findings.
(B) Top experiments for FAM175A reveal a stoichiometric complex between FAM175A, UIMC1, and BRE/BRCC36/C19orf62, but not with FAM175B (3).
3N analyses for FAM175B (C) and UIMC1 (D) show that all IPs that have FAM175A predominantly contain UIMC1 and BRCA1 (4) and thus reveal autonomous
FAM175A/B uniCOREs.
(E) MORF4L1/2 MEMO interacts with BRCA1/BARD1/PALB2/BRCA2 uniCORE and also forms uniCOREs with chromatin-remodeling complexes SIN3B and
BRD8.additional uniCOREs with transcriptional coregulator complexes
SIN3B and BRD8 (Figure 2E), highlighting widespread heteroge-
neity in protein complex organization.790 Cell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc.The BRCA example illustrates that interactome modules are
separable by data analysis in silico. Moreover, a hierarchical
representation of CCIs via MEMOs and uniCOREs is an
appropriate way to illustrate these distinct, biologically relevant
entities. As we continue to appreciate the modularity in protein
complexes, it becomes increasingly sensible to catalog the
divergence of cellular networks anchored in proteins shared by
multiple uniCOREs. In retrospect, the BASC complex we re-
ported 10 years ago is actually a merged representation of
BRCA1 CCI networks (Wang et al., 2000) that now also include
other components (Feng et al., 2009; Kim and Chen, 2008;
Shao et al., 2009a, 2009b; Zhang et al., 2009). Thus, our
HT-IP/MS study allows a ‘‘systems view’’ of the BRCA1 network,
predicting various PPI dynamics and their vitality in biology. This
is a testimony for the merit of a single-source HT-IP/MS effort,
where uniform experimental conditions are applied and more
consistent data are obtained for the analysis of context-depen-
dent CCI networks.
Iterative Interrogation Reveals CCI Topology
Themost effective way tomine our data is to iteratively search for
proteins within a particular CCI network to reveal nuances in
network organization. For example, when the largest RNA poly-
merase Pol II subunit (POLR2A) is used as the seed, six known
Pol II subunits are found along with most subunits of the
Mediator and Integrator complexes, RPAP2, GPN1/GPN3,
SPEN, ZMYND8/ZNF687/ZNF592, and CDK9/CCNT1 and ELL
elongation complexes (Figures 3A and 3B). Reciprocal searches
using MED15, INTS7, or RPAP2 all preferentially return Pol II
subunits, confirming these extensive interactions (Figure S3).
Closer inspection of the data shows that the RPAP2 network
lacks Mediator coactivator but has GPN1/GPN3 and Integrator.
Therefore, RPAP2 likely resides in a subnetwork of Pol II where
Integrator and Mediator separate. Analysis of the MED15 data
shows that this protein is found in two exclusive complexes:
it is a part of the large Mediator complex but also interacts
separately with an E3 ligase, TRIM11, which binds and degrades
MED15 (Ishikawa et al., 2006). Our data imply that TRIM11
sequesters the MED15 subunit away from the main body of the
Mediator complex to form a relatively stable and discrete
complex. Accordingly, we have singled outMED15 as a separate
MEMO to account for this exclusive interaction pattern.
Next we use SPEN (split ends homolog; a.k.a., SHARP) as an
example of a single-coregulator MEMO at the crossroads of
different transcriptional processes. SPEN CCI analysis reveals
previously unappreciatedprotein interactions (Figure 3C). SPEN’s
associations with Mediator explain its presence in the Pol II
network. This analysis also reveals the HDAC3/NCOR core-
pressor complex as a prominent interaction partner of SPEN.
Finally, we recover SPEN interactions with aWTAP (Wilm’s tumor
1 associated protein) mRNA splicing complex, independently
from HDAC3/NCOR and Mediator. Collectively, SPEN appears
at the intersection of at least three seminal processes of eukary-
otic transcription: chromatin-remodeling, transcriptional initiation,
andmRNAprocessing. TheseSPEN interactions also explain how
it can act as either a coactivator or a corepressor of transcription.
To our knowledge, this is the first attempt to comprehensively
investigate and address how diverse patterns of associations in
HT-IP/MS datasets translate into a tiered organization of
complex-complex interactions on a proteome scale. Next, we
use transcriptional coregulators to show how this resource canbe used to better understand existing, and to explore unex-
pected, connections in transcriptional regulation.
Nuclear Receptor Transcriptional Regulation
TheNURSAConsortium curates andmaintains a tally of over 300
NR coregulators (Lanz et al., 2006) (http://www.nursa.org and
Table S1). In our dataset, 128 NR coregulators were recovered
as direct antigens (see Figure 1B for examples), while an
additional 185 were identified as interacting proteins or in unin-
tended cross-reacting complexes. We can confidently assign
170 MEMOs that contain 211 known NR coregulators and
300 additional proteins that are likely coregulators. Further-
more, CCI networks of NR coregulators currently show >3700
unique gene products that participate in coregulation. This is
a considerable expansion of the NURSA coregulator list, sug-
gesting that many more proteins can participate in the regulation
of NR-driven transcription than previously thought.
Deconvolution of the CCI Network of SRC-3 Reveals
a Distinct Interactive Subset of NR Coregulators
We noticed that many NR coregulators, although recovered at
high numbers in multiple reciprocal IPs, did not consistently
form preferred interactions. Such promiscuous interaction
patterns were observed most often for multifunctional coregula-
tors that perform extremely diverse cellular functions. We there-
fore broadly classify transcriptional coregulators into two
classes according to the type of protein complexes they form.
Type I coregulators exist in relatively stable multisubunit
steady-state complexes and show little variation in their compo-
sition, thus conforming to our conventional image of a protein
complex. Examples of type I complexes include well-known
Mediator (Gu et al., 1999), nucleosome remodeling and deacety-
lase (NURD) complexes (Xue et al., 1998), CoREST complex
(Hakimi et al., 2002), HDAC3/NCOR (Guenther et al., 2000),
and SWI/SNF (BAF/P-BAF) (Kaeser et al., 2008; Wang et al.,
1996), all of which we recovered fully in our IP/MS dataset, along
with lesser known RANBP9, PELP1 (Figure 4A and Figure S4A),
and the Z3 complexes described below.
The type II coregulators, on the other hand, do not have
consistent steady-state stoichiometric partners and often
resolve into one-componentMEMOs (Figure 4B and Figure S4B).
Such substoichiometric associations likely represent the hall-
mark behavior for many coregulators, which is to provide a quick
response to different cellular signals through dynamic context-
specific associations. The oncogenic SRC-3 (a.k.a., AIB1 or
NCOA3) is a prime example of a type II coregulator.
The multifunctional transcriptional coregulator SRC-3 is
a common target for cellular growth programs (Anzick et al.,
1997; Kuang et al., 2004; Torres-Arzayus et al., 2004; Lonard
et al., 2007; Yan et al., 2006), adipogenic and energy balance
(Louet et al., 2006; Coste et al., 2008), and control of mRNA
translation of proinflammatory cytokines (Yu et al., 2007). Such
functional diversity may be provided by associated proteins,
which bind SRC-3 proteins that are differentially modified post-
translationally in response to the activation of different signaling
pathways (Li et al., 2008; O’Malley et al., 2008; York et al., 2010).
SRC-3 itself is a target of multiple cell signaling pathways (Font
de Mora and Brown, 2000; Giannı` et al., 2006; Wu et al., 2004;Cell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc. 791
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Yan et al., 2008; Yi et al., 2008) and acts as an integrator by
converging signals to the genome for modulation of target
gene expression. Our 3N analyses show only substoichiometric
interaction patterns in the SRC-3 interactome, even for well-
proven associations such as CBP/p300 and REGg (PSME3) (Fig-
ure 4B). Along with the interacting coregulators, a diverse
number of NRs, such as ERa, RXRa/b, and COUP-TFII, along
with frequent tethering partners such as AP-1, coprecipitated
with SRC-3 in our IP experiments. Importantly, this type II
behavior is preserved in MCF-7 breast cancer cells described
in our earlier study (Lanz et al., 2010). These observations
suggest that type II behavior is an inherent and cell-type-inde-
pendent property of this molecule, and quite possibly also of
many other type II transcriptional coregulators.
The ability to distinguish type I from type II molecules serves as
a good illustration of the conceptually different insights gained by
a large-scaleproteomicsstudy,whosediscovery-drivencharacter
is better positioned to reveal general perceptions, such as the
overall biological functions of a type II protein. A classification of
transcriptional coregulators based on their ‘‘interactivity’’ helped
us to better understand why some coregulators have been re-
ported to be responsible for many different cellular processes,
whereasothers seem toexert specializedbiology only, albeit func-
tioning in different signal and gene contexts. For type IImolecules,
variability of interactants found in individual experiments for such
proteins is overcome by analyzing large single IP/MS studies like
the one presented here. It then becomes clear that a protein that
biochemically appears not to form a consistent complex often
displays the most complicated regulatory interaction networks,
indicating its important functional significance at the CCI level
rather than in the formation of core complexes. The identification
of type II interacting partners is indispensable for the under-
standing of regulatory processes and will remain an important
challenge for affinity-based approaches and for translational
efforts. This is certainly the case for oncogenic SRC-3.
The Z3 Coregulator Complex Participates
with an Extensive CCI Network
Among hitherto unspecified coregulators, our work revealed
a transcriptional coregulator complex whose number of interac-
tions rivals that of Mediator or Integrator (Figure 5A). This Z3
MEMO consists of ZMYND8, ZNF687, and ZNF592. ZMYND8
contains a PHD-finger, a Bromodomain, a Pro-Trp-Trp-Pro
(PWWP) motif, and a MYND-type zinc finger and is likely to func-
tion as a reader of histone modifications. It recently has been
suggested to affect chromatin silencing (Poleshko et al., 2010)
and to interact with the transcriptional coregulator RCOR2
(Zeng et al., 2010). ZNF687 and ZNF592 have multiple C2H2
zinc fingers known to bind DNA.Figure 3. Iterative Mining of HT-IP/MS Resource Reveals Topology of
(A and B) 3N analyses for POLR2A show three separate subnetworks containing R
and Figure S6). The MEMOs in the POLR2A network were grouped by patterns of
independent of each other.
(C) Coregulator SPEN stands on crossroads of three seminal transcriptional pr
Mediator and chromatin remodeling via HDAC3/NCOR complex. SPEN also cop
SFRS and WTAP complexes. (*) Heatmap column headers specify antibody na
antibody data, see Table S1).Z3 forms a uniCORE with a two-protein MEMO made of
TSPYL1/TSPYL2 (testis-specificproteinY-like 1 and2) (Figure 5A
and Figure S5A). The Integrator protein complex appears to be
the predominant partner of Z3, bringing Pol II into the Z3 CCI
network. Z3 also is frequently found associated with the H3K4
demethylation machinery, including the H3K4me2/me1 deme-
thylase KDM1 uniCORE, a partnering H3K4me3 demethylase
KDM5A-containing SIN3B complex, and KDM5C H3K4me3 de-
methylase. Such conglomeration of histonemodification readers
suggests a prominent role for Z3 biology in interpreting the
histone code for remodeling of chromatin for transcription. In
addition, Z3 co-occurs with many transcription factors in our
IP/MS dataset, including the nuclear receptor NR4A1 (NUR77,
Figure S5B) and ERa, which we discuss next.
ERa interacts with the Z3 network at substoichiometric levels
(Figure 5B) in MCF-7 breast cancer cells. We confirmed this by
coimmunoprecipitation (co-IP) and in vitroGSTpull-downassays
(Figures 5C and 5D and Figure S5C). Furthermore, ChIP-seq
analysis showed a significant overlap of ZMYND8 chromatin-
binding sites with known ERa-binding sites (Figure 5E and Fig-
ureS5D).Wealso confirmed transcriptional coactivator functions
of ZMYND8 in ERa-driven reporter assays and on endogenous
E2-dependent genes (Figures 5F and 5G). siRNA knockdown of
ZMYND8 showed markedly decreased transcription at the
presumptive ERa/Z3 target genes ADORA1 and NAV2, whereas
the classical ERa targetspS2/TFF1 andGREB1 appear to be less
affected (Figure 5G), suggesting likely gene specificity of
ZMYND8. This example again demonstrates the potential of our
CCI resource to serve as abasis for deriving testable hypotheses.
Bridging the Gap between Genome-wide Data
and Functional Proteomic Analyses
Currently, genome-wide association studies are identifying
common genetic factors that impact health and disease. Even
at an early stage the linking of genomics and proteomics data
can further our understanding of disease pathways and provide
platforms for generation of hypotheses. For example, in
oncology, it is imperative to distinguish causative driver muta-
tions from ‘‘hitchhiking’’ passengers (Stratton et al., 2009).
Based on the premise that protein complexes function as biolog-
ical units, we must imply that proteins that physically associate
with known cancer drivers ‘‘collectively’’ confer a selective
growth advantage on cells. These ‘‘guilt-by-association co-
drivers’’ thus appear as additional valuable targets for functional
translational analyses and therapeutic interventions. Cellular
protein complexomes such as the resource presented here
can complement genomic data with most valuable proteomics
information, thus leading to a better understanding and treat-
ments of human cancers.RNA Polymerase II Network
PAP2-GPN1/3, Integrator complex, and Mediator complex (see also Figure S3
their distribution to show that Mediator and Integrator subnetworks are vividly
ocesses. Its CCI network suggests an association with transcription through
recipitates with proteins that regulate splicing process, including multisubunit
mes, not the intended antigens that were used to generate the antibody (for
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Figure 4. Coregulators Show Two Classes of Protein Interaction
Profiles
3N analyses broadly classify coregulator networks into having either stable
preferential protein networks (type I) or multiple transient interactions (type II)
(heatmaps and additional examples are shown in Figure S4).
794 Cell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc.In Figure 6 we show two examples of the accrual of oncoge-
netic data in protein complexes. We used the Sanger Cancer
Gene Census resource of human oncogenic mutations (Futreal
et al., 2004) as well as the Broad Institute’s Tumorscape data-
base, which lists copy number changes across multiple cancer
types (Beroukhim et al., 2010), to flag cancer-related gene
products in our protein complex networks (see also Figure S6).
In the P-BAF uniCORE, for example, an overwhelming number
of complex components have different associations with
cancers (Figure 6A), strongly suggesting a key physiological
role of this chromatin-remodeling complex as a whole in
oncogenesis, and implying that its subunits are functionally
more likely to be drivers rather than passengers.
Similarly, the SIN3B uniCORE has three subunits that are
significantly amplified in breast cancers (C11orf30, GATAD1,
PHF12), whereas two more proximal components (KDM5A,
ZNF131) are amplified in epithelial lineages (Figure 6B) (Berou-
khim et al., 2010). Among these, C11orf30 (EMSY) and KDM5A
were identified as drivers in breast cancers (Brown et al., 2010;
Raouf et al., 2005; Santarius et al., 2010) and in acute myeloid
leukemia (Futreal et al., 2004; Glaros et al., 2007; Wang et al.,
2009b), respectively. Although the other gene products in this
complex have not yet been causally implicated in cancer, our
finding that they reside in a stable complex with validated cancer
drivers predicts that they also are likely to provide a selective
advantage to clonal cell expansions.
Perspectives
Here, we present a large-scale HT-IP/MS dataset and discuss
examples of extensive interaction networks derived from endog-
enous human regulatory protein complexes. Our approach
serves as an operational framework for the deconvolution of
high-content proteomics data and testifies to the feasibility of
mapping the endogenous protein complexome on a proteome-
wide scale in higher eukaryotes.
The dense reciprocity of protein associations in our IP/MS
dataset ensures high-confidence assignments and provides
the highest standard of verification for native protein-protein
interactions. The analysis of multiple reciprocal immunoprecipi-
tations forgoes the necessity to exhaustively characterize the
specificity of primary antibodies and produces a low number of
false positive designations.
We recovered most published core complexes and have
found many previously undocumented complex subunits. We
also accomplished a characterization of weak protein interac-
tions beyond most prior studies. As a result, we offer our hierar-
chical organization of endogenous protein complex interactions
as a three-tiered organization of stable MEMOs, which combine(A) Schematic illustrations of examples of type I NR coregulators with previ-
ously unidentified subunits. Green: coregulators listed at NURSA.org; E1, D2,
D1, B1, and D3 are SMARC subunits; B7A, B, C are BCL7A, B, and C; C20,
C20orf11; C17, C17orf39; BP9 and BP10 are RANBP9 and RANBP10; Y5,
YPEL5, respectively.
(B) 3N heatmap excerpt for SRC-3/NCOA3. This is a typical type II coactivator
that lacks stoichiometric steady-state complex while revealing a multitude of
substoichiometric interactions, such as CBP (CREBBP), p300 (EP300),
REG-gamma (PSME3), and various transcription factors (TFs).
to form variant core complexes (uniCOREs) that then interact
with each other to form CCIs. Our resource includes snapshots
of high-order associations between regulatory complexes and
serves as an initial roadmap for understanding the human
interactome.
Because endogenous protein complexes were isolated and
identified, our method is directly transferable to any cell line in
culture and will be extended to isolated tissues in the near future.
This is particularly important when specificity for cell types and
sensitivity to challenges such as hormonal treatments or exoge-
nous stress must be considered to delineate particular context-
dependent interactions. Ultimately, mapping the context-depen-
dent interactomes is a molecular requisite for understanding
cellular biology.
This study emphasized nuclear transcriptional coregulators
and in type I and type II complexes revealed two broadly distinct
coregulator interaction patterns. Further, we argue that when
intelligently combined with genomics and transcriptomics data,
proteomics information provides a rationale and predictable
understanding of phenotype that has a real potential for
translation. Our recurrent finding that cancer gene products
group together in select protein complexes supports the idea
that the perturbation of a protein complex as a whole should
be implicated in the etiology of malignancies, entailing all
complex constituents as valuable molecular targets for disease
screening and therapy. This same logic can be applied to the
etiology of polygenic metabolic or central nervous system
diseases, where mutations in multiple genes are responsible
for a disorder. We postulate that in many cases, polygenic muta-
tions compromise the physiologic function within a single multi-
protein complex, and then additional mutations further degrade
the function of the particular interaction network above the
threshold for disease progression. In this manner, our resource
will provide ample ideas for further testing of the involvement
of coregulatory proteins in the development of human polygenic
diseases.
Taken together, genomics, proteomics, and targeted func-
tional studies comprise three critical components of the combi-
natorial ‘‘systems’’ approach that can be employed to effectively
translate genomics data into molecular knowledge in order to
ultimately advance clinical applications.
EXPERIMENTAL PROCEDURES
Cell Culture and Nuclear Extraction
HeLa S3 were cultured in suspension in 20–36 l spin bottles in RPMI-1640
media with 5% FBS to final density of 0.5 3 106 cells/ml. Attached cell lines
were grown in 50 to 200 15-cmplates in DMEMwith 5%FBS. Cell fractionation
was done as previously described (Malovannaya et al., 2010). For HeLa S3,
nuclear extraction with 0.02–1.2M KCl buffer titration was applied; for MCF-
7 cells, the 300–900 mM KCl gradient was used. Resulting 500 mM salt
extract was dialyzed to 160 mM KCl.
Immunoprecipitation
IPs were carried out essentially as described (Malovannaya et al., 2010).
Briefly, nuclear extracts were ultracentrifuged (200,000 rcf) after thawing;
0.5–1 ml extract (10–15 mg) was incubated with 7–15 mg primary antibody
for 2 hr followed by ultracentrifugation and 45 min incubation with Sephar-
ose-CL4B Protein A beads (GE Healthcare). Minimal bead washing with NTN
(50mMTris-Cl, pH 8.0, 150mMNaCl, 0.5%NP-40) was used to preserve tran-sient interactions. Information about intended and predicted antigens of
particular antibodies can be found in Table S1.
SDS-PAGE and Mass Spectrometry
Immunocomplexes were eluted in 13 Laemmli buffer and resolved on pre-cast
4%–20% Novex Tris-Glycine or 4%–12% NuPage gels (Invitrogen, CA, USA)
to half-length. Gels were minimally stained with Coomassie brilliant blue, cut
into 6 molecular weight ranges and heavy chain IgG band, and digested with
trypsin. Immunocomplexes were identified on a Thermo Fisher LTQ (majority)
or Velos-Orbitrap mass spectrometers. Spectral data were then searched
against human protein RefSeq database in BioWorks or Proteome Discoverer
Suites with either SeQuest (for LTQ data) or Mascot (Orbitrap data) software.
Multi-consensus result files of protein GI identifiers were compiled for each
IP with strict filters and often manually inspected.
Data Processing
IP/MS results were transferred into an in-house built FileMaker-based rela-
tional database where protein identification numbers (protein GIs) were con-
verted to the GeneID identifiers according to the NCBI ‘‘gene2accession’’
table. Data filtering and deconvolution were performed as described in the
text and in Extended Experimental Procedures.
Overexpression and Reciprocal co-IP
293T cells were transiently transfected with expression constructs for
estrogen receptor (pCR3.1-hERa), pEGFP-C1-ZMYND8 (inserted at BglII/
EcoRI sites), or control plasmids using Lipofectamine 2000 (Invitrogen).
Forty-eight hours after transfection, cells were lysed in BC lysis buffer
(20 mM Tris-HCl, pH 7.5, 0.2 mM EDTA, 20% glycerol, 0.15 M NaCl, 0.5%
NP40, 10 mM b-ME, and protease inhibitors [PIs]), and lysates were centri-
fuged at 100,000 rcf and immunoprecipitated using 1 mg anti-ER (SC-8002,
SCBT), anti-GFP (custom, Genemed Synthesis), or control rabbit/mouse IgG
mix (Cell Signaling), followed by SDS-PAGE and western blotting.
RNA Interference and Real-Time Quantitative PCR
3 3 105 MCF-7 cells were transfected with 100 pmoles siRNA against
ZMYND8 (HSS119059 and 1199061) or Negative Control Medium CG Content
#2 siRNA (Invitrogen) using Lipofectamine RNAiMAX reverse transfection
protocol. Cells were changed to 5% stripped serum DMEMmedia w/o phenol
red at 16 hr and at 36 hr treated with 10 nM b-estradiol (Sigma) and collected
24 hr after treatment. Total RNA was isolated using RNeasy kit (QIAGEN);
cDNA was prepared using SSIII RT system (Invitrogen) and analyzed by quan-
titative RT-PCR on ABI 7500 or StepOne Plus thermocyclers (Applied Biosys-
tems) using SYBR Green (Applied Biosystems/LifeTechnologies) and gene-
specific primers (see Figure S5D).
Luciferase Reporter Assays
HeLa cells were transfected with pCR3.1-hERa, pERE-E1b-LUC, pCMV-
Tag2-SRC3, pCRIITOPO-ZMYND8, and/or control vectors using Lipofect-
amine 2000 (Invitrogen) and cultured in 5% stripped serum-containing
DMEM w/o phenol red. Forty-eight hours after transfection, cells were treated
overnight with 10 nM b-estradiol or ethanol vehicle, lysed in luciferase lysis
buffer (25 mM Tris-HCl, pH8.0, 150 mM NaCl, 0.5% Triton X-100, 10%
glycerol, 1 mM EDTA, 1 mM DTT, PIs), and luciferase was measured using
Promega luciferase assay system on Centro LB960 luminometer (Berthold
Technologies).
GST Pull-Down
GST fusion proteins (Figure S5C) were produced in BL21 bacteria (Stratagene)
using 0.5 mM IPTG induction. Bacterial pellets were lysed in NETN buffer
(50 mM Tris-HCl, pH8.0, 150 mMNaCl, 0.5% NP40, 5 mM EDTA, PIs), cleared
by ultracentrifugation, and bound to glutathione sepharose 4B (GE Healthcare)
for 1 hr at 4C. Beads were washed with NETN, and amount of GST protein
was estimated by SDS-PAGE followed by Coomassie staining. GST fusion
proteins or control GST bound to beads were preincubated with 100 ml
NETN containing 10 mg/ml BSA for 1 hr at 4C to block nonspecific binding.
Recombinant estrogen receptor was obtained from Invitrogen, diluted in
NETN to 0.2 mg/ml, and cleared by ultracentrifugation. One hundredmicrolitersCell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc. 795
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Figure 5. Z3 Complex Is a Transcriptional Coregulator
(A) Concise representation of the Z3 CCI network showing extensive interaction connections to transcriptional machinery (see also Figures S5A and S5B). Pol
II-Integrator network (*) is omitted due to space limitations. In addition to histone demethylases KDM5C, KDM5A, and KDM1 (see text), Z3 also interacts with
ASC1 (TRIP4) coregulator. (#) P-BAF, Polybromo and Brg/Brahma-Associated Factor (see Figure 4A for BAF). Known NR coregulators are shown in green.
(B) Reciprocal IP/MS of Z3 proteins with ERa in MCF-7 cells.
(C) Reciprocal IP/WB of overexpressed GFP-ZMYND8 and ERa in 293T cells; (1) and (2) are corresponding inputs.
(D) In vitro binding suggests that binding to ERa is via the N-terminal portion of ZMYND8 (Z8-F1). Asterisks indicate positions of ZMYND8 fragments.
(E) UCSC browser examples showing co-occupancy of ERa and ZMYND8-binding sites at E2-upregulated genes.
796 Cell 145, 787–799, May 27, 2011 ª2011 Elsevier Inc.
A 
ARID1A 
SMARCA4*
BCL7B 
SMARCA2 
SMARCC1 
SMARCC2 
SMARCD1 
SMARCE1 
SS18/18L1*
ARID2 
PHF10 
PBRM1 
de
le
te
d 
a
m
pl
ifie
d 
BCL7A* 
SMARCB1*
ARID2 
PBRM1 BRD7 
PHF10 
SMARCC2 
ARID1A 
ARID1B 
SMARCA4 
SMARCA2 
   SMARCD3 
 SMARC 
D1 
SMARC 
D2 
SS18/L 
SMARC
E1 
  BCL7A 
BCL7C 
SMARC
B1 
DPF2 
 BCL7B 
ACTL6A 
SMARCC1 
B 
MORF4L1 
KDM5A 
C11orf30 
SIN3B 
PHF12 
GATAD1 
MORF4L2 KDM5A* 
C11orf30*
PHF12 
GATAD1 
a
m
pl
ifie
d 
KDM5C KDM5C* 
ZNF131 
ZNF677 
FOXK2 
ZHX1 
ZNF131 
Figure 6. Cancer Gene Alterations Group within Protein Complex
Modules
(A) The P-BAF complex is significantly perturbed in lung cancers. Red:
amplified; dark blue: deleted in non-small cell lung cancer (NSCLC); light blue:
deleted in lung lineages.
(B) The SIN3B uniCORE is a hub of proteins with genomic amplifications. All
but two proteins of the SIN3B complex are significantly amplified in breast
cancer lineages (dark red) or epithelial lineages (pink). All genesmarkedwith an
asterisk are listed in Cancer Gene Sensus (Futreal et al., 2004) and/or have
been implicated causally in cancer development. Amplification and deletions
are marked according to Tumorscape resource (Beroukhim et al., 2010).of ERa solution was added to 100 ml of bead-bound domains and incubated for
20 min at 4C, followed by triple NETN washes. Pull-downs were analyzed by
western blotting.
Genome-wide ZMYND8 Location Analysis by ChIP-Sequencing
Chromatin immunoprecipitation was performed according to the protocol
from Upstate Biotechnology with minor modifications. 1 3 107 MCF-7 cells
were used for each ChIP after 45 min treatment with 10 nM b-estradiol. After
sonication the chromatin fraction was immunoprecipitated with CBC2032(F) ZMYND8 coactivates ERa in reporter luciferase assay; error bars represent s
(G) RNAi knockdown of ZMYND8 compromises upregulation of someE2-responsi
deviation of three 18S-normalized mRNA measurements.ZMYND8 antibody and freed by heating. The ChIP-seq data were processed
using MACS 1.3.5 with p values 1e8 and fold-change greater than 40 for
peak calls.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at doi:10.
1016/j.cell.2011.05.006. CCI networks of nuclear receptor coregulators have
been incorporated into NURSA molecular pages and standalone resource
solutions are available for downloading at the NURSA website (http://www.
nursa.org).
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